



Applicant(s): Chi Vu et al.  
U.S.S.N.: 10/552,306

**Amendments to the Claims**

1. (Currently Amended) A compound of the following formula:



or a pharmaceutically acceptable salt or N-oxide thereof;

wherein


A is 2-furanyl;

B is N;


each of R<sup>2</sup> and R<sup>3</sup> is independently hydrogen or alkyl, cycloalkyl, cycloalkenyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, or heteroaralkyl;

each of X<sup>1</sup> and X<sup>2</sup> is independently hydrogen, C<sub>1-6</sub> alkylene, C<sub>2-6</sub> alkenylene, C<sub>2-6</sub> alkynylene or a bond;

L is a bond or a linker selected from the group consisting of:



Applicant(s): Chi Vu et al.  
U.S.S.N.: 10/552,306



wherein:

each of R' and R'', independently, is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, acyl, halo, hydroxy, amino, nitro, oxo, thioxo, cyano, guanadino, amidino, carboxy, sulfo, sulfoxyl, mercapto, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, aminocarbonyl, alkylcarbonylamino, alkylsulfonylamino, alkoxycarbonyl, alkylcarbonyloxy, urea, thiourea, sulfamoyl, sulfamide, carbamoyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfanyl, heterocycloalkyl, heterocycloalkyloxy, heterocycloalkylsulfanyl, aryl, aryloxy, arylsulfanyl, aroyl, heteroaryl,

Applicant(s): Chi Vu et al.  
U.S.S.N.: 10/552,306

heteroaryloxy, heteroarylsulfanyl, or heteroaroyl; provided that two adjacent R' groups can join together to form a 4- to 8-membered optionally substituted cyclic moiety;

X<sup>a</sup> is -C(R<sup>2</sup>)(R<sup>3</sup>)-, -S-, -SO-, or -SO<sub>2</sub>-;

X<sup>b</sup> is -C(R<sup>2</sup>)(R<sup>3</sup>)-, -NR<sup>2</sup>-, -O-, -S-, -SO-, or -SO<sub>2</sub>-;

each of p, q, m and m1, independently, is 0-3;

r is 1 or 2;

n1 is 0-6; and


n2 is 2-6;

Y is -C(R<sup>2</sup>)(R<sup>3</sup>)-, -O-, -S-, -SO-, -SO<sub>2</sub>-, -CO-, -CO<sub>2</sub>-, or a bond; and

R<sup>1</sup> is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, or heterocycloalkyl;


provided that

(1) when each of X<sup>1</sup> is a bond and L is a 4- to 6-membered saturated heterocyclic group selected from the group consisting of:



(2) when L is a bond, X<sup>1</sup> is an alkynylene.

2. (Original) The compound of claim 1, wherein X<sup>1</sup> is C<sub>2-6</sub> alkynylene.




3. (Currently Amended) The compound of claim 2, wherein L is a bond, [[;]]

4. (Original) The compound of claim 2, wherein X<sup>2</sup> is C<sub>1-4</sub> alkylene or a bond.


Applicant(s): Chi Vu et al.  
U.S.S.N.: 10/552,306

5. (Original) The compound of claim 2, wherein Y is a bond.
6. (Canceled)
7. (Original) The compound of claim 2, wherein R<sup>1</sup> is alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl.
8. (Original) The compound of claim 7, wherein R<sup>1</sup> is optionally substituted with alkyl, halo, hydroxy or phenyl.




9. (Currently Amended) The compound of claim 2, wherein L is a bond; X<sup>2</sup> is C<sub>1-4</sub> alkylene or a bond; Y is a bond; ~~each of R<sup>2</sup> and R<sup>3</sup> is independently hydrogen or alkyl~~; R<sup>1</sup> is alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl, each of which being optionally substituted with alkyl, halo, hydroxy, or phenyl; ~~A is heteroary~~, and B is N.

Applicant(s): Chi Vu et al.  
U.S.S.N.: 10/552,306



10. (Original) The compound of claim 1, wherein L is



11. (Original) The compound of claim 10, wherein  $X^b$  is  $-C(R^2)(R^3)-$  or  $-NR^2-$ .

12. (Original) The compound of claim 11, wherein  $X^b$  is  $-C(R^2)(R^3)-$ .

13. (Original) The compound of claim 12, wherein p is 0-1 and q is 1.

14. (Original) The compound of claim 13, wherein n1 is 1-4 and n2 is 2-4.

15. (Original) The compound of claim 14, wherein  $X^1$  is C<sub>1-6</sub> alkylene or a bond.

16. (Original) The compound of claim 14, wherein  $X^2$  is C<sub>1-6</sub> alkylene or a bond.

17. (Original) The compound of claim 14, wherein Y is  $-SO_2-$ ,  $-CO-$ ,  $-CO_2-$ , or a bond.


18. (Canceled)

Applicant(s): Chi Vu et al.  
U.S.S.N.: 10/552,306

19. (Original) The compound of claim 14, wherein R<sup>1</sup> is aryl or heteroaryl, each of which being optionally substituted with alkyl, halo, hydroxy, or phenyl.


20. (Currently Amended) The compound of claim 14, wherein each of X<sup>1</sup> and X<sup>2</sup> is independently C<sub>1-6</sub> alkylene or a bond; Y is -SO<sub>2</sub>-, -CO-, -CO<sub>2</sub>-, or a bond; ~~each of R<sup>2</sup> and R<sup>3</sup> is independently hydrogen or alkyl;~~ and R<sup>1</sup> is aryl or heteroaryl, each of which being optionally substituted with alkyl, halo, hydroxy, or phenyl.

21. (Currently Amended) The compound of claim 14, wherein L is



; X<sup>1</sup> is a bond, X<sup>2</sup> is C<sub>1-4</sub> alkylene; Y is a bond; ~~each of R<sup>2</sup> and R<sup>3</sup> is independently hydrogen or alkyl;~~ R<sup>1</sup> is aryl or heteroaryl, each of which being optionally substituted with alkyl, halo, hydroxy, or phenyl; ~~A is heteroaryl;~~ and B is N.

22. (Original) The compound of claim 1, wherein L is



23. (Original) The compound of claim 22, wherein X<sup>1</sup> is C<sub>1-6</sub> alkylene, C<sub>2-6</sub> alkynylene, or a bond.

24. (Original) The compound of claim 22, wherein X<sup>2</sup> is C<sub>1-6</sub> alkylene or a bond.

Applicant(s): Chi Vu et al.  
U.S.S.N.: 10/552,306

25. (Original) The compound of claim 22, wherein Y is  $-SO_2-$ ,  $-CO-$ ,  $-CO_2-$ , or a bond.

26. (Canceled)

27. (Original) The compound of claim 22, wherein  $R^1$  is alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl.

28. (Original) The compound of claim 27, wherein  $R^1$  is optionally substituted with alkyl, halo, hydroxy or phenyl.

29. (Currently Amended) The compound of claim 22, wherein  $X^1$  is  $C_{1-6}$  alkylene,  $C_{2-6}$  alkynylene, or a bond,  $X^2$  is  $C_{1-6}$  alkylene or a bond; Y is  $-SO_2-$ ,  $-CO-$ ,  $-CO_2-$ , or a bond; ~~each of~~  $R^2$  and  $R^3$  is independently hydrogen or alkyl;  $R^1$  is alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl, each of which is being optionally substituted with alkyl, halo, hydroxy, or phenyl; A is heteroaryl; and B is N.

30. (Original) The compound of claim 1, said compound being

2-furan-2-yl- $N^5$ -[1-(5-methyl-isoxazol-3-ylmethyl)-pyrrolidin-2-ylmethyl]-  
[1,2,4]triazolo[1,5-a]pyridmidine-5,7-diamine;  
2-furan-2-yl- $N^5$ -methyl- $N^5$ -[1-(5-methyl-isoxazol-3-ylmethyl)-pyrrolidin-2-ylmethyl]-  
[1,2,4]triazolo[1,5-a]pyridmidine-5,7-diamine;  
 $N^5$ -[1-(2,5-difluoro-benzyl)-pyrrolidin-2-ylmethyl]-2-furan-2-yl-[1,2,4]triazolo[1,5-  
a]pyrimidine-5,7-diamine;  
5-{3-[4-(2,4-difluoro-phenyl)-piperaziny-1-yl]prop-1-ynyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-  
a]pyrimidin-7-ylamine;  
5-{3-[4-(2,4-difluoro-phenyl)-piperaziny-1-yl]propyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-  
a]pyrimidin-7-ylamine;  
5-{3-[4-(2,4-difluoro-phenyl)-piperaziny-1-yl]ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-  
a]pyrimidin-5,7-diamine;

Applicant(s): Chi Vu et al.  
U.S.S.N.: 10/552,306

$N^5\{-2-[4-(2,4\text{-difluoro-phenyl})\text{-piperaziny-1-yl}]\text{ethyl}\}\text{-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine}$ ;  
 $2\text{-furan-2-yl-}N^5\{-1\text{-furan-2-ylmethyl-pyrrolidin-2-ylmethyl}\}\text{-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $N^5\{-1\text{-(2-fluorobenzyl)\text{-pyrrolidin-2-ylmethyl}}\}\text{-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $2\text{-furan-2-yl-}N^5\{-1\text{-pyridin-2-ylmethyl-pyrrolidin-2-ylmethyl}\}\text{-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $2\text{-furan-2-yl-}N^5\{-1\text{-pyridin-4-ylmethyl-pyrrolidin-2-ylmethyl}\}\text{-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $2\text{-furan-2-yl-}N^5\{-1\text{-(2,3,6-trifluorobenzyl)\text{-pyrrolidin-2-ylmethyl}}\}\text{-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $N^5\{-1\text{-(2-chloro-pyridin-4-ylmethyl)\text{-pyrrolidin-2-ylmethyl}}\}\text{-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $1\text{-(7-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-ylethynyl)\text{-cyclopentanol}}$ ;  
 $1\text{-(7-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-ylethynyl)\text{-cyclohexanol}}$ ;  
 $2\text{-furan-2-yl-}N^5\{-2\text{-[4-(2,4,6-trifluorophenyl)\text{-piperaziny-1-yl}]\text{ethyl}\}\text{-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $N^5\{-2\text{-[4-(2,3-difluorophenyl)\text{-piperazin-1-yl}]\text{ethyl}\}\text{-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $2\text{-furan-2-yl-}N^5\{-2\text{-[4-(3,4,5-trifluorophenyl)\text{-piperazin-1-yl}]\text{ethyl}\}\text{-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $2\text{-furan-2-yl-}N^5\{-2\text{-[4-(2,3,6-trifluorophenyl)\text{-piperazin-1-yl}]\text{ethyl}\}\text{-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $N^5\{-2\text{-[4-(3,5-difluorophenyl)\text{-piperazin-1-yl}]\text{ethyl}\}\text{-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $N^5\{-2\text{-[4-(2,6-difluorophenyl)\text{-piperazin-1-yl}]\text{ethyl}\}\text{-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $N^5\{-2\text{-[4-(2,5-difluorophenyl)\text{-piperazin-1-yl}]\text{ethyl}\}\text{-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;

Applicant(s): Chi Vu et al.  
U.S.S.N.: 10/552,306

$N^5\{-2-[4-(2\text{-fluorophenyl})\text{piperazin-1-yl}]\text{ethyl}\}\text{-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $N^5\{-2-[4-(4\text{-fluorophenyl})\text{piperazin-1-yl}]\text{ethyl}\}\text{-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $N^5\{-2-[4-(3,5\text{-dichlorophenyl})\text{piperazin-1-yl}]\text{ethyl}\}\text{-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $2\text{-furan-2-yl-}N^5\{-2-[4-(2,3,4\text{-trifluorophenyl})\text{piperazin-1-yl}]\text{ethyl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $2\text{-furan-2-yl-}N^5\{-2-[4-(2,4,5\text{-trifluorophenyl})\text{piperazin-1-yl}]\text{ethyl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ; and  
 $N^5\{-2-[4-(4\text{-chloro-2-fluorophenyl})\text{piperazin-1-yl}]\text{ethyl}\}\text{-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ . [[;]]

31. (Original) The compound of claim 1, said compound being  
 $2\text{-furan-2-yl-}N^5\{-1-(5\text{-methyl-isoxazol-3-ylmethyl})\text{pyrrolidin-2-ylmethyl}\}\text{-[1,2,4]triazolo[1,5-a]pyridmidine-5,7-diamine}$ ;  
 $2\text{-furan-2-yl-}N^5\text{-methyl-}N^5\{-1-(5\text{-methyl-isoxazol-3-ylmethyl})\text{pyrrolidin-2-ylmethyl}\}\text{-[1,2,4]triazolo[1,5-a]pyridmidine-5,7-diamine}$ ;  
 $2\text{-furan-2-yl-}N^5\{-1\text{-furan-2-ylmethyl-pyrrolidin-2-ylmethyl}\}\text{-[1,2,4]triazolo[1,5-a]pyridmidine-5,7-diamine}$ ;  
 $N^5\{-1-(2,5\text{-difluoro-benzyl})\text{pyrrolidin-2-ylmethyl}\}\text{-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $2\text{-furan-2-yl-}N^5\{-1-(2,3,6\text{-trifluorobenzyl})\text{pyrrolidin-2-ylmethyl}\}\text{-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $N^5\{-1-(2\text{-chloro-pyridin-4-ylmethyl})\text{pyrrolidin-2-ylmethyl}\}\text{-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine}$ ;  
 $1\text{-}(7\text{-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-ylethynyl})\text{-pentanol}$ ;  
 $1\text{-}(7\text{-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-ylethynyl})\text{-cyclohexanol}$ ;  
 $5\text{-}(3\text{-cyclohexyl-prop-1-ynyl})\text{-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine}$ ;

Applicant(s): Chi Vu et al.  
U.S.S.N.: 10/552,306

5-{3-[4-(2,4-difluoro-phenyl)-piperaziny-1-yl]prop-1-ynyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;  
N<sup>5</sup>-{2-[4-(2,4-difluoro-phenyl)-piperziny-1-yl]ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;  
2-furan-2-yl-N<sup>5</sup>-{2-[4-(2,4,6-trifluorophenyl)-piperaziny-1-yl]-ethyl}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
N<sup>5</sup>-{2-[4-(2,3-difluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
2-furan-2-yl-N<sup>5</sup>-{2-[4-(2,3,6-trifluorophenyl)-piperazin-1-yl]-ethyl}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
N<sup>5</sup>-{2-[4-(2-fluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
N<sup>5</sup>-{2-[4-(4-fluorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
N<sup>5</sup>-{2-[4-(3,5-dichlorophenyl)-piperazin-1-yl]-ethyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine; and  
2-furan-2-yl-N<sup>5</sup>-{2-[4-(2,3,4-trifluorophenyl)-piperazin-1-yl]-ethyl}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine.

32. (Original) The compound of claim 1, said compound being

2-furan-2-yl-N<sup>5</sup>-[1-(5-methyl-isoxazol-3-ylmethyl)-pyrrolidin-2-ylmethyl]-[1,2,4]triazolo[1,5-a]pyridmidine-5,7-diamine;  
2-furan-2-yl-N<sup>5</sup>-methyl-N<sup>5</sup>-[1-(5-methyl-isoxazol-3-ylmethyl)-pyrrolidin-2-ylmethyl]-[1,2,4]triazolo[1,5-a]pyridmidine-5,7-diamine;  
N<sup>5</sup>-[1-(2,5-difluoro-benzyl)-pyrrolidin-2-ylmethyl]-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;  
5-(3-cyclohexyl-prop-1-ynyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;  
5-{3-[4-(2,4-difluoro-phenyl)-piperaziny-1-yl]prop-1-ynyl}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;

Applicant(s): Chi Vu et al.  
U.S.S.N.: 10/552,306

$N^5\{-2-[4-(2,4-difluoro-phenyl)-piperziny-1-yl]ethyl\}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine;$   
 $2-furan-2-yl-N^5\{-2-[4-(2,4,6-trifluorophenyl)-piperaziny-1-yl]-ethyl\}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;$   
 $N^5\{-2-[4-(2-fluorophenyl)-piperazin-1-yl]-ethyl\}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine;$   
 $N^5\{-2-[4-(3,5-dichlorophenyl)-piperazin-1-yl]-ethyl\}-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine; and$   
 $2-furan-2-yl-N^5\{-2-[4-(2,3,4-trifluorophenyl)-piperazin-1-yl]-ethyl\}-[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diamine.$

33. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

34. (Original) A pharmaceutical composition comprising a compound of claim 30 and a pharmaceutically acceptable carrier.

35-46. (Canceled)

47. (Previously Presented) The compound of claim 10, wherein  $X^1$  is  $C_{1-6}$  alkylene,  $C_{2-6}$  alkynylene or a bond.

48. (Previously Presented) The compound of claim 47, wherein  $R^2$  is hydrogen or alkyl.

49. (Previously Presented) The compound of claim 48, wherein  $X^2$  is  $C_{1-6}$  alkylene or a bond.

50. (Previously Presented) The compound of claim 49, wherein  $Y$  is  $-SO_2-$ ,  $-CO-$ ,  $-CO_2-$ , or a bond.

Applicant(s): Chi Vu et al.  
U.S.S.N.: 10/552,306

51. (Previously Presented) The compound of claim 50, wherein R<sup>1</sup> is alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl.

52. (Previously Presented) The compound of claim 51, wherein R<sup>1</sup> is a substituted aryl (e.g., 2,4-difluorophenyl).

53. (Previously Presented) The compound according to claim 10, wherein X<sup>1</sup> is C<sub>1-6</sub> alkylene, C<sub>2-6</sub> alkynylene or a bond; Y is -SO<sub>2</sub>-, -CO-, -CO<sub>2</sub>-, or a bond; R<sup>1</sup> is alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl; and X<sup>2</sup> is C<sub>1-6</sub> alkylene or a bond.